Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Prof. Nawwar Al-Attar
Transcatheter valve implantation has introduced a new concept in the management of valve disease. Surgeons and cardiologists team up with anesthetists and imaging specialists to provide a novel multidisciplinary approach to treat patients otherwise refused traditional surgery or classical interventional cardiology.
Aortic valve stenosis is the commonest native valve disease in Europe (1). Treatment is indicated in severe aortic stenosis and when patients experience symptoms. Surgical replacement of the aortic valve by a mechanical or biological prosthesis performed under cardiopulmonary bypass has been the only practical therapeutic option available for these patients. This procedure has an acceptable operative mortality even in elderly patients and provides good long term results.
Nevertheless, patients with significant comorbidities or previous patent coronary artery bypass grafts are often denied surgery given the high operative risk and considerable mortality. This has been demonstrated in the Euro Heart Survey, where around 30% of patients with severe aortic valve disease and symptoms were not proposed to the surgeon.
In 2002, Cribier et al reported the first case of percutaneous transcatheter implantation of an aortic valve prosthesis for aortic stenosis in man (2). This “salvage” procedure was initially reserved for companionate cases where the risk of death after conventional surgery was considered too important. It does not require cardiopulmonary bypass or aortic cross clamping and may be performed under locoregional anesthesia and sedation. As the name implies the prosthesis is “implanted” and does not “replace” the native valve. Since the first case, the technique has been employed in a number in centers within specific study protocols in certain indications. The procedure can be performed either by :
Two devices are currently available:
Results published in medical literature (3,4) of this technique include elderly patients contraindicated to surgery or at a considerably high risk or as expressed by elevated STS Predicted Risk of Mortality score or EuroScore. After careful selection of patients, procedural success is high (90% for the transapical approach). Adequate diameter of femoral and iliac vessels is a sine que non for the transfemoral approach. Congruity between aortic annulus (determined by preoperative work up) and size of available prosthesis is another determinant factor for both techniques.
In-hospital mortality at 30 days ranges from 5 to 18%. Valve area after implantation ranges from 1.5 to 1.8cm² and shows an adequately functional valve by echocardiographic studies 6-12 months after implantation. Embolic complications, namely stroke, have been reported to be lower in the transapical than the transfemoral approach. This is probably due to less catheter manipulation in the aortic arch. Access routes complications particularly with the transfemoral approach are another important source of complications (5).
Fields of progress include improvement in introducer and valve size as well as in the quality of the imaging technique, many of which are already in progress. Another interesting indication for this approach are patients with a degenerated bioprosthesis. Implantation of a transcatheter valve inside the previous bioprosthesis avoids the risk of redo surgery (6) and widen the horizons for early implantation of bioprosthesis should the procedure prove its efficacy, safety and “long term” reliability.
Figure 1. The Edwards-Sapien valve
Figure 2. The CoreValve percutaneous aortic valve
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on valvular disease. Eur Heart J 2003;24:1231-1243
2. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis:first human case description. Circulation 2002;106:3006-3008
3. Walther T, Falk V, Kempfert J, Borger MA, Fassl J, Chu MW, Schuler G, Mohr FW. Transapical minimally invasive aortic valve implantation; the initial 50 patients. Eur J Cardiothorac Surg. 2008 Feb 20; [Epub ahead of print]
4. Webb JG, Pasupati S, Humphries K, Thompson C, Altwegg L, Moss R, Sinhal A, Carere RG, Munt B, Ricci D, Ye J, Cheung A, Lichtenstein SV. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation. 2007;116:755-63.
5. Himbert D, Al Attar N, Depoix J-P, Nataf P, Vahanian A. Prise en charge de la sténose aortique du sujet âgé : un travail d’équipe. Cardiologie Pratique. 2008; 831 :1-8.
6. Walther T, Falk V, Dewey T, Kempfert J, Emrich F, Pfannmüller B, Bröske P, Borger MA, Schuler G, Mack M, Mohr FW. Valve-in-a-valve concept for transcatheter minimally invasive repeat xenograft implantation. Am Coll Cardiol. 2007;50:56-60.
Vol 6 N°29
Dr N. Al-Attar Paris, France Web editor for the working group on cardiovascular surgery
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved